Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BLINCYTO vs AFINITOR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bispecific CD19-directed CD3 T-cell engager; binds CD19 on B cells and CD3 on T cells, activating endogenous T cells to lyse CD19-expressing B cells.
Inhibitor of mammalian target of rapamycin (m TOR), specifically the m TORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.
Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and children,B-cell precursor ALL in first or second complete remission with minimal residual disease (MRD) ≥0.1% in adults and children
Advanced hormone receptor-positive, HER2-negative breast cancer in postmenopausal women in combination with exemestane after failure of letrozole or anastrozole,Progressive neuroendocrine tumors of pancreatic origin (PNET) in unresectable, locally advanced or metastatic disease,Advanced renal cell carcinoma (RCC) after failure of sunitinib or sorafenib,Subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC) in patients requiring therapeutic intervention but not amenable to curative resection
Continuous intravenous infusion over 28 days per cycle. For patients ≥45 kg: 9 mcg/day on days 1-7 and 28 mcg/day on days 8-28 for cycle 1, then 28 mcg/day on days 1-28 for subsequent cycles. For patients <45 kg: 5 mcg/m2/day on days 1-7 and 15 mcg/m2/day on days 8-28 for cycle 1, then 15 mcg/m2/day on days 1-28 for subsequent cycles. Hospitalization recommended for first 9 days of cycle 1 and first 2 days of subsequent cycles.
10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/m L).
The terminal elimination half-life of blinatumomab is approximately 2.11 hours (range 1.2–2.5 hours) during continuous intravenous infusion. The short half-life necessitates continuous infusion to maintain therapeutic concentrations.
Terminal elimination half-life: 30 hours (range 15–40 hours) in healthy subjects; increases to 40–70 hours in moderate hepatic impairment.
Metabolized to small peptides by catabolic pathways; not metabolized by CYP enzymes.
Substrate of CYP3A4; metabolized primarily by CYP3A4; also a substrate of P-glycoprotein (P-gp).
Blinatumomab is not metabolized by cytochrome P450 enzymes; it is expected to be degraded into small peptides and amino acids via catabolic pathways. No specific excretion studies have been conducted; however, clearance is primarily through non-specific proteolysis, and no significant renal or biliary excretion of intact drug occurs. The contribution of renal elimination to total clearance is minimal (<1%).
Primarily fecal (80%) and renal (5%) as unchanged drug and metabolites. Biliary excretion is significant.
Blinatumomab is a monoclonal antibody; protein binding is negligible at clinically relevant concentrations. No specific binding to plasma proteins has been reported.
74% bound to plasma proteins (primarily albumin and α1-acid glycoprotein).
The volume of distribution (Vd) at steady state is approximately 3.13 L (range 2.35–4.38 L), corresponding to about 0.04 L/kg (assuming 70 kg body weight), suggesting limited extravascular distribution consistent with a large monoclonal antibody.
Mean steady-state Vd: 342 L (approx. 4.9 L/kg in a 70 kg adult), indicating extensive tissue distribution.
Blinatumomab is administered as a continuous intravenous infusion; bioavailability by this route is 100%. No other routes are clinically relevant.
Oral bioavailability: approximately 16% (low due to P-glycoprotein efflux and first-pass metabolism); food reduces variability but does not alter AUC significantly.
No dose adjustment recommended for mild to moderate renal impairment (Cr Cl ≥30 m L/min). For severe renal impairment (Cr Cl <30 m L/min) or dialysis, use with caution and monitor for increased toxicity; specific dose adjustments not established.
No dose adjustment for mild to moderate renal impairment (Cr Cl >=30 m L/min). For severe renal impairment (Cr Cl <30 m L/min): reduce dose to 5 mg once daily. End-stage renal disease (Cr Cl <15 m L/min): use with caution, no specific recommendation.
No dedicated Child-Pugh based adjustments available. Use with caution in patients with moderate to severe hepatic impairment; monitor for hepatotoxicity.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose to 5 mg daily; Child-Pugh C: reduce dose to 2.5 mg daily, or consider alternate therapy.
For patients weighing ≥45 kg: same as adult dosing. For patients <45 kg: based on body surface area (BSA). Cycle 1: 5 mcg/m2/day (max 9 mcg/day) on days 1-7, then 15 mcg/m2/day (max 28 mcg/day) on days 8-28. Subsequent cycles: 15 mcg/m2/day (max 28 mcg/day) on days 1-28. Administer as continuous IV infusion over 28 days.
For SEGA: 5 mg/m^2 orally once daily, adjusted to achieve everolimus trough concentrations of 5-15 ng/m L. Dose adjustments per AUC or tolerability. Not approved for other indications in children.
No specific dose adjustment recommended for elderly patients. Monitor closely for adverse reactions, particularly neurologic events and infections, as clinical studies included limited patients aged ≥65 years.
No specific dose adjustment; start at recommended adult dose. Monitor for increased risk of infections, stomatitis, and metabolic effects due to age-related decline in organ function.
Cytokine release syndrome (CRS), which may be life-threatening or fatal; neurological toxicities, including immune effector cell-associated neurotoxicity syndrome (ICANS), which may be severe or fatal.
No black box warnings.
Cytokine release syndrome, neurological toxicities (including ICANS), infections, neutropenia and febrile neutropenia, tumor lysis syndrome, leukopenia, increased liver enzymes, pancreatitis, preparation and administration errors, and embryo-fetal toxicity.
Non-infectious pneumonitis,Infections (including opportunistic infections),Hypersensitivity reactions including anaphylaxis,Angioedema,Renal failure,Impaired wound healing,Metabolic effects (hyperglycemia, dyslipidemia),Myelosuppression,Immunosuppression leading to increased risk of infections,Cases of fatal hemorrhage in patients with history of bleeding,Radiation sensitization and recall reactions, especially in patients with previous radiation therapy,Increased risk of pneumocystis jirovecii pneumonia (PJP) and other opportunistic infections; consider prophylaxis,Avoid live vaccines
Known hypersensitivity to blinatumomab or any component of the formulation.
Hypersensitivity to everolimus, sirolimus, or any component of the formulation
No clinically significant food interactions reported. Grapefruit and grapefruit juice do not affect blinatumomab as it is a monoclonal antibody not metabolized by CYP450 enzymes. No dietary restrictions required.
Avoid grapefruit, grapefruit juice, and Seville oranges (including marmalade) due to CYP3A4 inhibition increasing everolimus levels. Take consistently with or without food, but high-fat meals reduce absorption. Avoid St. John's wort.
Based on its mechanism of action (CD19-directed bispecific T-cell engager) and animal studies, blinatumomab may cause fetal harm. Ig G molecules cross the placenta, with increasing transfer in the second and third trimesters. Limited human data exist; however, it is expected to pose a risk of fetal B-cell lymphopenia, immunomodulation, and potential teratogenicity. Use during pregnancy should be avoided unless the benefit clearly outweighs the risk.
Pregnancy Category D. Positive evidence of human fetal risk. Based on its mechanism of action (m TOR inhibitor) and animal studies, AFINITOR (everolimus) is embryotoxic and fetotoxic. First trimester exposure carries risk of structural anomalies; second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and renal impairment. Use only if benefit outweighs risk.
There are no data on blinatumomab presence in human milk, effects on the breastfed child, or milk production. Due to the potential for serious adverse reactions from a large Ig G protein, breastfeeding is not recommended during treatment and for at least 48 hours after the last dose.
No data on presence in human milk, effects on breastfed infant, or milk production. M/P ratio unknown. Breastfeeding is not recommended due to potential adverse effects on the developing immune system and growth.
No specific dose adjustments for pregnancy have been established. Pregnancy may alter pharmacokinetics (e.g., increased volume of distribution, altered clearance), but data are insufficient to recommend dose changes. Use with caution and monitor for toxicity.
No specific dose adjustments established for pregnancy. Pharmacokinetic changes in pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce drug exposure; however, given the teratogenic risk, use during pregnancy should be avoided. If unavoidable, consider therapeutic drug monitoring if available and adjust dose to achieve target trough concentrations (typically 3-8 ng/m L for transplant indications; for oncology, refer to specific protocol).
Premedicate with corticosteroids (e.g., dexamethasone 20 mg IV) 1 hour before infusion to reduce the risk of cytokine release syndrome (CRS). Monitor for neurological toxicities, including seizures and encephalopathy, especially during the first 2 doses. Dose adjustments are required for patients with renal impairment (Cr Cl < 30 m L/min). Blinatumomab is administered as a continuous IV infusion over 28 days per cycle; do not flush the line to prevent bolus administration.
Monitor renal function and blood glucose regularly; Afinitor (everolimus) can cause non-infectious pneumonitis, so obtain baseline chest imaging and assess for new or worsening respiratory symptoms. Adjust dose for moderate hepatic impairment (Child-Pugh B). Avoid live vaccines during treatment.
This medication is given as a continuous infusion through a vein over 28 days; you will have a portable infusion pump.,Common side effects include fever, chills, headache, and nausea; these are often manageable with medications.,Seek immediate medical attention if you experience severe headache, confusion, seizures, difficulty speaking, or vision changes (signs of neurological toxicity).,Report any signs of infection such as fever, chills, or sore throat; blinatumomab can lower your white blood cell count.,Do not disconnect, adjust, or stop the infusion pump without consulting your healthcare provider.
Take Afinitor at the same time each day, consistently either with or without food.,Avoid grapefruit, grapefruit juice, and Seville oranges during treatment.,Report any new or worsening cough, chest pain, or difficulty breathing immediately.,Monitor for signs of infection such as fever, chills, or sore throat; avoid large crowds and sick individuals.,Use effective contraception during treatment and for 8 weeks after stopping.,Do not crush or chew tablets; swallow whole with a glass of water.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BLINCYTO vs AFINITOR, answered by our medical review team.
BLINCYTO is a Antineoplastic Monoclonal Antibody that works by Bispecific CD19-directed CD3 T-cell engager; binds CD19 on B cells and CD3 on T cells, activating endogenous T cells to lyse CD19-expressing B cells.. AFINITOR is a mTOR Inhibitor Antineoplastic that works by Inhibitor of mammalian target of rapamycin (m TOR), specifically the m TORC1 complex, by binding to the FKBP-12 protein, reducing cell proliferation, angiogenesis, and glucose uptake.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BLINCYTO and AFINITOR depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BLINCYTO is: Continuous intravenous infusion over 28 days per cycle. For patients ≥45 kg: 9 mcg/day on days 1-7 and 28 mcg/day on days 8-28 for cycle 1, then 28 mcg/day on days 1-28 for subsequent cycles. For patients <45 kg: 5 mcg/m2/day on days 1-7 and 15 mcg/m2/day on days 8-28 for cycle 1, then 15 mcg/m2/day on days 1-28 for subsequent cycles. Hospitalization recommended for first 9 days of cycle 1 and first 2 days of subsequent cycles.. The standard adult dose of AFINITOR is: 10 mg orally once daily for advanced breast cancer, neuroendocrine tumors, and renal cell carcinoma; 10 mg orally once daily for subependymal giant cell astrocytoma (SEGA) in adults; 5 mg/m^2 orally once daily for SEGA in pediatric patients (titrated to trough levels 5-15 ng/m L).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BLINCYTO and AFINITOR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BLINCYTO is classified as Category C. Based on its mechanism of action (CD19-directed bispecific T-cell engager) and animal studies, blinatumomab may cause fetal harm. IgG molecules cross the placenta, with increasing . AFINITOR is classified as Category C. Pregnancy Category D. Positive evidence of human fetal risk. Based on its mechanism of action (mTOR inhibitor) and animal studies, AFINITOR (everolimus) is embryotoxic and fetotoxi. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.